NASDAQ$SRTA
Strata Critical Medical Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Strata Critical Medical reported Q3 2025 net income of $57.4M with diluted EPS of $0.70.
Third-quarter net income was $57.4 million, primarily reflecting $67.1 million from discontinued operations, while continuing operations posted a net loss of $9.7 million. Diluted EPS was $0.70 versus $(0.03) a year ago.
- Q3 net income $57.4M including discontinued ops gain.
- Continuing operations net loss $9.7M.
- Diluted EPS $0.70.
- Flight profit metrics discussed in MD&A.
Headline financials
Revenue & EPS history
Strata Critical Medical · Revenue · Quarterly
$49.3M
Forward guidance
The filing discusses Strata Critical Medical's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Strata Critical Medical cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
Headwinds
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+3.4%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+5.7%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+38.8%
Q3 2023
Best reaction
-32.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.6% | +17.2% | +19.7% | |
| Q4 2025 | +6.9% | +1.1% | -7.6% | |
| Q3 2025 | +9.5% | +8.1% | +4.3% | |
| Q1 2025 | +18.7% | +20.5% | +41.4% | |
| Q4 2024 | +7.1% | +8.1% | -4.9% | |
| Q3 2024 | -4.4% | -17.5% | +8.9% | |
| Q2 2024 | +17.3% | +3.6% | +2.9% | |
| Q1 2024 | -3.3% | -3.3% | -16.0% | |
| Q4 2023 | -32.1% | -32.3% | -3.5% | |
| Q3 2023 | +38.8% | +44.5% | +44.5% | |
| Q2 2023 | -7.9% | -6.7% | -24.3% | |
| Q1 2023 | +9.4% | +2.8% | +28.1% | |
| Q4 2022 | -9.7% | -22.3% | -32.0% | |
| Q3 2022 | -2.3% | -0.2% | +3.4% | |
| Q2 2022 | +8.0% | +6.9% | -17.5% | |
| Q1 2022 | -15.0% | +0.9% | -2.3% | |
| Q4 2021 | -3.2% | +5.2% | -2.0% | |
| Q3 2021 | +0.3% | +2.1% | +41.4% | |
| Q2 2021 | +18.0% | +16.4% | +58.7% | |
| Q1 2021 | +13.7% | +11.8% | -11.8% | |
| Q4 2020 | -0.1% | -0.1% | +3.1% | |
| Q2 2020 | +0.0% | -0.2% | -0.1% | |
| Q1 2020 | +1.0% | +1.0% | +1.3% | |
| Q4 2019 | -0.2% | -0.3% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro